Historical Valuation
Cardinal Health Inc (CAH) is now in the Overvalued zone, suggesting that its current forward PE ratio of 20.58 is considered Overvalued compared with the five-year average of 13.00. The fair price of Cardinal Health Inc (CAH) is between 106.03 to 149.04 according to relative valuation methord. Compared to the current price of 201.11 USD , Cardinal Health Inc is Overvalued By 34.94%.
Relative Value
Fair Zone
106.03-149.04
Current Price：201.11
34.94%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cardinal Health Inc (CAH) has a current Price-to-Book (P/B) ratio of -17.01. Compared to its 3-year average P/B ratio of -9.65 , the current P/B ratio is approximately 76.24% higher. Relative to its 5-year average P/B ratio of -6.17, the current P/B ratio is about 175.77% higher. Cardinal Health Inc (CAH) has a Forward Free Cash Flow (FCF) yield of approximately 9.11%. Compared to its 3-year average FCF yield of 9.76%, the current FCF yield is approximately -6.72% lower. Relative to its 5-year average FCF yield of 10.50% , the current FCF yield is about -13.22% lower.
P/B
Median3y
-9.65
Median5y
-6.17
FCF Yield
Median3y
9.76
Median5y
10.50
Competitors Valuation Multiple
AI Analysis for CAH
The average P/S ratio for CAH competitors is 0.52, providing a benchmark for relative valuation. Cardinal Health Inc Corp (CAH.N) exhibits a P/S ratio of 0.19, which is -64.52% above the industry average. Given its robust revenue growth of 22.44%, this premium appears sustainable.
Performance Decomposition
AI Analysis for CAH
1Y
3Y
5Y
Market capitalization of CAH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CAH in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CAH currently overvalued or undervalued?
Cardinal Health Inc (CAH) is now in the Overvalued zone, suggesting that its current forward PE ratio of 20.58 is considered Overvalued compared with the five-year average of 13.00. The fair price of Cardinal Health Inc (CAH) is between 106.03 to 149.04 according to relative valuation methord. Compared to the current price of 201.11 USD , Cardinal Health Inc is Overvalued By 34.94% .
What is Cardinal Health Inc (CAH) fair value?
CAH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cardinal Health Inc (CAH) is between 106.03 to 149.04 according to relative valuation methord.
How does CAH's valuation metrics compare to the industry average?
The average P/S ratio for CAH's competitors is 0.52, providing a benchmark for relative valuation. Cardinal Health Inc Corp (CAH) exhibits a P/S ratio of 0.19, which is -64.52% above the industry average. Given its robust revenue growth of 22.44%, this premium appears sustainable.
What is the current P/B ratio for Cardinal Health Inc (CAH) as of Jan 09 2026?
As of Jan 09 2026, Cardinal Health Inc (CAH) has a P/B ratio of -17.01. This indicates that the market values CAH at -17.01 times its book value.
What is the current FCF Yield for Cardinal Health Inc (CAH) as of Jan 09 2026?
As of Jan 09 2026, Cardinal Health Inc (CAH) has a FCF Yield of 9.11%. This means that for every dollar of Cardinal Health Inc’s market capitalization, the company generates 9.11 cents in free cash flow.
What is the current Forward P/E ratio for Cardinal Health Inc (CAH) as of Jan 09 2026?
As of Jan 09 2026, Cardinal Health Inc (CAH) has a Forward P/E ratio of 20.58. This means the market is willing to pay $20.58 for every dollar of Cardinal Health Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cardinal Health Inc (CAH) as of Jan 09 2026?
As of Jan 09 2026, Cardinal Health Inc (CAH) has a Forward P/S ratio of 0.19. This means the market is valuing CAH at $0.19 for every dollar of expected revenue over the next 12 months.